Insurance Bureau issued the "Announcement on the Results of the Negotiations for the Su Yansu Xutonghuai Public Medical Institutions' Medical Consumables Alliance to Bring Volume Renewal and Expansion", showing:>
Pioneering pharmaceutical proclosamine treatment of severe new crown patients clinical trial death risk reduced by 92%
Time of Update: 2021-03-22
Hospital stay shortened by 9 days544px;white-space:normal;background-color:#FFFFFF;box-sizing:border-box !important;'> 544px;text-align:justify;background-color:#FFFFFF;box-sizing:border-box !important;overflow-wrap:break-word !important;'> Prokalamide treatment group (N=294) Placebo control group (N=296) Number of people percentage Number of people percentage mortality rate 11 3.
Health and Wellness Commission: 30 new crown confirmed 92 cases of local 73 cases
Time of Update: 2021-02-02
(Shanghai 7 cases, Liaoning 3 cases, Guangdong 3 cases, Fujian 2 cases, Shaanxi 2 cases, Jiangsu 1 case, Sichuan 1 case), 73 local cases (63 cases in Jilin, 9 cases in Heilongjiang, 1 case in Hebei); 135 new cases were cured and discharged from
CD19 CAR-T Cell Therapy! Gilead Yescarta Treatment Recurrence/Difficult Inert Non-Hodgkin's Lymphoma (iNHL): Total remission rate of 92%!
Time of Update: 2020-12-18
data released at the ASH Annual Meeting showed that after receiving Yescarta's single infusion treatment, the medium follow-up was 17.5 months: 92% of the 104 patients with assessable efficacy were in remission (ORR-92%) and 76% were fully relieved (CR-76%).
in Meshadon: complete 2 years of Keytruda treatment of patients with a 3-year survival rate of 92%!
Time of Update: 2020-11-02
compared to pure chemotherapy (n-63): (1) objective remission rate (ORR:58% vs 33%) was significantly increased, and medium remission duration (DOR) was extended by more than one year (36) .3 months) vs 22.8 months) ;(2) No progression lifetime
Total mitigation rate of 92%! FDA grants Gilead CD47 single anti-magrolimab breakthrough drug: Treatment of bone marrow growth syndrome!
Time of Update: 2020-10-07
September 16, 2020 // -- Gilead Sciences recently announced that the U.S. Food and Drug Administration (FDA) has granted magolimab Breakthrough Drug Qualification (BTD), the first anti-CD47 monoclonal antibody to treat newly diagnosed myeloid growth syndrome (MDS).
Junshi Bio announced its interim results for 2020, with research and development investment up 92% year-on-year!
Time of Update: 2020-09-28
press release, the company has made significant progress in product commercialization, clinical trials and pipeline expansion, with unaudited revenue of $575 million, up 86% year-on-year.
for New Allergies: Hematological Remission Rate Up to 92%
Time of Update: 2020-09-26
September 11, 2020 // -- Johnson and Johnson (JNJ)'s Janssen Pharmaceuticals recently announced that it has filed a Supplemental Biologics Licensing Application (SBLA) with the U.S. Food and Drug Administration (FDA) seeking approval for Darzalex
hydroxybutyrate magnesium potassium), reducing sodium intake by 92%!
Time of Update: 2020-07-28
The U.S. Food and Drug Administration () has approved an oral solution (sodium hydroxybutylate, potassium, magnesium, calcium) for the treatment of denarcing or excessive daytime drowsiness in patients with narcolepsy (narcolepsy) and older
Death toll from bird flu in Indonesia rises to 92
Time of Update: 2020-07-06
Indonesia is currently one of the worst countries to have an avian influenza outbreak, with more than 110 people infected with the highly pathogenic avian influenza virus, of whom 92 have died.
Johnson and Johnson Darzalex combination of first-line treatment AL Phase III Clinical: Hematology remission rate as high as 92%
Time of Update: 2020-06-26
Original source: Subcutane Daratumab Combination Results in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in The Treatment of Patients with Diagnosed Light Chain (AL) Amyloidosis the original title: Light Chain (AL
Interpretation of exclusive medical insurance bureau: 92% of consumables are eliminated
Time of Update: 2020-06-19
in this regard, sabilan instruments visited the relevant person in charge of the bidding and Purchasing Department of Liaoyang medical insurance bureau to learn about the negotiation and quotation in this centralized purchase.
combination first-line therapy Phase III Clinical: Hematology remission rate as high as 92%
Time of Update: 2020-06-16
June 14, 2020 /PRNewswire/ -- Janssen Pharmaceuticals, owned by Johnson and Johnson (JNJ), recently announced the positive results of the Phase III ANDROMEDA study at the 25th annual meeting of the European Society of Haematology (EHA). The study
Hepatitis C new medicine! Gilead Epclusa has a virological cure rate of 92-95% in patients aged 6-18
Time of Update: 2020-06-01
For hCV children under 12 years of age, especially those infected with HCV genotypes 2 and 3, the approved HCV treatment optionishes are limited. In an open label study of pediatric patients aged 6-18 with HCV genotypes 1, 2, 3, 4, and 6, the Epclusa